178 related articles for article (PubMed ID: 37863852)
1. XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models.
Wang B; Liu Y; Yuan R; Dou X; Qian N; Pan X; Xu G; Xu Q; Dong B; Yang C; Li H; Wang J; Bai G; Liu L; Gao X
Cancer Immunol Immunother; 2023 Dec; 72(12):4015-4030. PubMed ID: 37863852
[TBL] [Abstract][Full Text] [Related]
2. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
4. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
5. Enhanced immunity against hepatoma induced by dendritic cells pulsed with Hsp70-H22 peptide complexes and CD40L.
Gao J; Luo SM; Peng ML; Deng T
J Cancer Res Clin Oncol; 2012 Jun; 138(6):917-26. PubMed ID: 22327301
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses.
Kelsall BL; Stüber E; Neurath M; Strober W
Ann N Y Acad Sci; 1996 Oct; 795():116-26. PubMed ID: 8958922
[TBL] [Abstract][Full Text] [Related]
9. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
10. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
11. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
[TBL] [Abstract][Full Text] [Related]
12. The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell-mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells.
Merz C; Sykora J; Marschall V; Richards DM; Heinonen K; Redondo Müller M; Thiemann M; Schnyder T; Fricke H; Hill O; Gieffers C
J Immunother; 2018; 41(9):385-398. PubMed ID: 30273198
[TBL] [Abstract][Full Text] [Related]
13. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
14. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.
Sadeghlar F; Vogt A; Mohr RU; Mahn R; van Beekum K; Kornek M; Weismüller TJ; Branchi V; Matthaei H; Toma M; Schmidt-Wolf IGH; Kalff JC; Strassburg CP; González-Carmona MA
Cancer Immunol Immunother; 2021 May; 70(5):1451-1464. PubMed ID: 33180184
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
Pandey MS; Wang C; Umlauf S; Lin S
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
[TBL] [Abstract][Full Text] [Related]
17. Immune Check Point CD40-CD40L Activates Dendritic and Effector Cells Against Human Renal Carcinoma Cells.
Hillebrand RM; Vogt A; Strassburg CP; Gonzalez-Carmona MA; Schmidt-Wolf IGH
Anticancer Res; 2019 Sep; 39(9):4643-4652. PubMed ID: 31519562
[TBL] [Abstract][Full Text] [Related]
18. Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma.
Serba S; Schmidt J; Wentzensen N; Ryschich E; Märten A
Gut; 2008 Mar; 57(3):344-51. PubMed ID: 17675324
[TBL] [Abstract][Full Text] [Related]
19. The PD-L1/4-1BB Bispecific Antibody-Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner.
Peper-Gabriel JK; Pavlidou M; Pattarini L; Morales-Kastresana A; Jaquin TJ; Gallou C; Hansbauer EM; Richter M; Lelievre H; Scholer-Dahirel A; Bossenmaier B; Sancerne C; Riviere M; Grandclaudon M; Zettl M; Bel Aiba RS; Rothe C; Blanc V; Olwill SA
Clin Cancer Res; 2022 Aug; 28(15):3387-3399. PubMed ID: 35121624
[TBL] [Abstract][Full Text] [Related]
20. Rapid induction of a novel costimulatory activity on B cells by CD40 ligand.
Wu Y; Xu J; Shinde S; Grewal I; Henderson T; Flavell RA; Liu Y
Curr Biol; 1995 Nov; 5(11):1303-11. PubMed ID: 8574588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
